The mere mention of the term “comparative effectiveness” evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. With President Obama calling for a national agency for comparative effectiveness, no one doubts that it is coming to healthcare—but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare?
Join us on Thursday, June 25 at 2:00 PM (EDT), as Tommy Bramley, senior director for Xcenda, and Tracy Foster, president for Lash Group, present insights that address:
- An overview of comparative effectiveness and an update of its
progress at the federal level
- Perspectives about comparative effectiveness from managed
care stakeholders
- How manufacturers can evaluate their risk and prepare for additional
requests for comparative analysis data
- What manufacturers can do to ensure continued patient access
to products
- How manufacturers can validate ongoing clinical and economic
benefits for their products
Register for this FREE Webcast!
PharmExec Blog
Follow Us
RSS
Bookstore
Upcoming Webcast: The Unvarnished Truth about Comparative Effectiveness
The mere mention of the term “comparative effectiveness” evokes a host of reactions among pharmaceutical manufacturers: confusion, skepticism, even fear. With President Obama calling for a national agency for comparative effectiveness, no one doubts that it is coming to healthcare—but what will it encompass? How will comparative effectiveness impact access to medications? What can manufacturers do to prepare?
Join us on Thursday, June 25 at 2:00 PM (EDT), as Tommy Bramley, senior director for Xcenda, and Tracy Foster, president for Lash Group, present insights that address:
progress at the federal level
care stakeholders
requests for comparative analysis data
to products
benefits for their products
Register for this FREE Webcast!